Slow-SPEED: Exercise for Early Parkinson's Disease

This study, called Slow-SPEED, is looking at whether a smartphone app can help people at risk for Parkinson's disease (PD) increase their physical activity. The goal is to see if more exercise can slow down the progression of early Parkinson's symptoms. You might be able to join if you are 50 or older, have specific genetic mutations (LRRK2 G2019S or GBA N370S) linked to a higher risk of PD, can walk on your own, and have a suitable smartphone. The study will track changes in your physical activity and a score that measures early Parkinson's signs over about three years. The study is currently unclear on its recruitment status and plans to enroll 600 participants.

Study design
This interventional study plans to enroll 600 participants. It uses a motivational smartphone application to encourage increased physical activity.
What's involved
Participants will use a smartphone app for 2 years to increase their daily steps and exercise intensity. Primary endpoints are measured from inclusion to week 156 (3 years).
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint for the composite prodromal load score is measured at the end of treatment (week 156), which is about 3 years after starting.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06993142

Slow-SPEED: Slowing Parkinson's Early Through Exercise Dosage

Recruiting
NAAges 50+InterventionalPrevention
Radboud University Medical Center
~600 participants
Updated 2026-08-27 on ClinicalTrials.gov
What's tested:Increase of physical activity volume and intensity with the use of a motivational smartphone application

At a glance

Recruiting sites
1 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in composite prodromal load score
Measured over From inclusion (week 0) to the end of treatment (week 156)
+1 more outcome measured
Parkinson Disease
Prodromal Stage
Neurodegenerative Diseases
Basal Ganglia Diseases
Central Nervous System Diseases
Synucleinopathies
Nervous System Diseases
Cerebral Disorder
Brain Diseases
Parkinsonian Disorders
Genetic Predisposition

NCT06993142

Where you'd take part

This study runs at 2 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Radboud University Medical Center

    Nijmegen, Gelderland, Netherlandsstudy coordinator listed

    Not yet recruiting

  • University of Rochester Center for Health and Technology (CHeT)

    Rochester, New Yorkstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

  • Sirwan KL Darweesh, PhD · PRINCIPAL_INVESTIGATOR · Radboudumc Department of Neurology

Opens a ready-to-send draft in your own email app — review before sending.

  • Change in composite prodromal load scoreFrom inclusion (week 0) to the end of treatment (week 156)

    Change in prodromal load score, comprised of digital biomarkers for prodromal symptoms. The score is currently under development.

  • Mean change in step count per dayAll 4 week periods between and including week -4 until 0 (baseline period) and week 152 until 156 (end of treatment)

    Mean change in step count per day as measured continuously with a smartwatch. Mean steps per day will be calculated from 4-week periods. Higher positive change in step count indicate more volume of physical activity.